{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:48:37Z","timestamp":1783475317078,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:p>Objective.\u2014To assess the efficacy and safety of topiramate for the prevention of pediatric migraine with or without aura in a double\u2010blind, randomized, placebo\u2010controlled trial.<\/jats:p>\n                  <jats:p>Background.\u2014Treatment options for pediatric migraine are currently limited, and no migraine preventive agents are approved for use in children in the United States. Topiramate is an effective migraine preventive therapy in adults, as demonstrated in several large, randomized, placebo\u2010controlled trials.<\/jats:p>\n                  <jats:p>Methods.\u2014One hundred and sixty\u2010two children with migraine (age, 6 to 15 years) were randomized in a 2:1 ratio to receive topiramate (n = 112) or placebo (n = 50). This study was designed to ensure that 150 participants were randomized to study medication. An additional 12 qualified patients were randomized because they had successfully completed the screening phase. The double\u2010blind phase of the trial consisted of a titration period and a maintenance period. Topiramate was initiated at 15 mg\/day and titrated over 8 weeks to 2 to 3 mg\/kg per day, or maximum tolerated dose, whichever was less (maximum allowed dose was 200 mg\/day). The target dose was maintained for 12 weeks. The primary efficacy variable was the change in mean number of migraine days per month (28 days) during the double\u2010blind phase relative to the 4\u2010week prospective baseline phase for each treatment group.<\/jats:p>\n                  <jats:p>\n                    Results.\u2014Topiramate treatment was associated with a mean reduction over the entire double\u2010blind phase of 2.6 migraine days per month, compared with a mean reduction of 2.0 migraine days per month for placebo (\n                    <jats:italic>P<\/jats:italic>\n                    = .061 topiramate vs. placebo). A significantly greater percentage of topiramate patients (32%) experienced a \u226575% reduction in mean monthly migraine days compared with placebo (14%,\n                    <jats:italic>P<\/jats:italic>\n                    = .02). Discontinuation rates due to adverse events were low: 6.5% for the topiramate group and 4.0% for the placebo group. The adverse events that occurred most commonly in the topiramate group at an incidence rate greater than in the placebo group were: upper respiratory tract infection, anorexia, weight decrease, gastroenteritis, paresthesia, and somnolence. The mean average daily dose of topiramate during the maintenance period was 2.0 mg\/kg per day.\n                  <\/jats:p>\n                  <jats:p>Conclusions.\u2014This pilot study suggests that topiramate may be an effective migraine preventive therapy in children. Topiramate was well tolerated in this population. Further randomized studies would be required to definitively establish the efficacy of topiramate for pediatric migraine prevention.<\/jats:p>","DOI":"10.1111\/j.1526-4610.2005.00262.x","type":"journal-article","created":{"date-parts":[[2010,8,13]],"date-time":"2010-08-13T10:01:22Z","timestamp":1281693682000},"page":"1304-1312","source":"Crossref","is-referenced-by-count":140,"title":["Topiramate for Migraine Prevention in Children: A Randomized, Double\u2010Blind, Placebo\u2010Controlled Trial"],"prefix":"10.1111","volume":"45","author":[{"given":"Paul","family":"Winner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Pearlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hulihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Topiramate Pediatric Migraine Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,11]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6957.765"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1997.3705269.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.1.e1"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2004.01.005"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.2223\/JPED.844"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0464-6"},{"key":"e_1_2_7_10_2","unstructured":"WinnerP JacobsD SchmittJ.Topiramate for migraine prevention in adolescent patients.Presented at: Annual Meeting of the American Academy of Neurology April 24\u2010May 1 2004 San Francisco California (Poster P02.102)."},{"issue":"1","key":"e_1_2_7_11_2","first-page":"A444","article-title":"Prophylaxis of pediatric headache with topiramate [abstract]","volume":"60","author":"Philipps TM","year":"2003","journal-title":"Neurology"},{"key":"e_1_2_7_12_2","unstructured":"FerreiraJ GarciaN PedeiraL.A case series of topiramate in pediatric and adolescent migraine prophylaxis.Presented at: American Academy of Neurology Annual Meeting April 13\u201020 2002 Denver Colorado (Abstract P06.119)."},{"key":"e_1_2_7_13_2","first-page":"456","article-title":"Topiramate in the treatment of pediatric migraine [abstract]","volume":"42","author":"Younkin DP","year":"2002","journal-title":"Headache"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02185.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1997.3709545.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100001931"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00062-6"},{"key":"e_1_2_7_18_2","first-page":"119","article-title":"The placebo problem in child and adolescent psychiatry","volume":"56","author":"Simeon JG","year":"1993","journal-title":"Acta Paedopsyhiatrica"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00089.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0041-87812002000600001"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00528.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1999.019008699.x"},{"key":"e_1_2_7_23_2","first-page":"399","article-title":"Topiramate in migraine prevention: A randomized, double\u2010blind placebo\u2010controlled trial [abstract]","volume":"42","author":"Silberstein S","year":"2002","journal-title":"Headache"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1338"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2005.00262.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2005.00262.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:58:16Z","timestamp":1762081096000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2005.00262.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1526-4610.2005.00262.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2005.00262.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}